Brokerages expect UroGen Pharma Ltd. (NASDAQ:URGN) to post earnings of ($1.27) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for UroGen Pharma’s earnings. The lowest EPS estimate is ($1.39) and the highest is ($1.08). UroGen Pharma reported earnings per share of ($1.38) during the same quarter last year, which suggests a positive year-over-year growth rate of 8%. The firm is expected to report its next earnings report on Thursday, March 17th.
On average, analysts expect that UroGen Pharma will report full-year earnings of ($4.86) per share for the current year, with EPS estimates ranging from ($5.08) to ($4.69). For the next year, analysts expect that the business will report earnings of ($3.33) per share, with EPS estimates ranging from ($4.28) to ($2.48). Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow UroGen Pharma.
UroGen Pharma (NASDAQ:URGN) last announced its quarterly earnings data on Monday, November 15th. The company reported ($1.35) EPS for the quarter, missing the consensus estimate of ($1.26) by ($0.09). UroGen Pharma had a negative net margin of 349.05% and a negative return on equity of 127.56%. During the same period in the previous year, the business posted ($1.31) EPS.
Several institutional investors and hedge funds have recently bought and sold shares of URGN. BlackRock Inc. raised its position in UroGen Pharma by 3.4% in the 2nd quarter. BlackRock Inc. now owns 1,727,039 shares of the company’s stock worth $26,372,000 after buying an additional 56,434 shares during the last quarter. RTW Investments LP purchased a new position in UroGen Pharma in the 3rd quarter worth about $14,423,000. Great Point Partners LLC purchased a new position in UroGen Pharma in the 3rd quarter worth about $12,615,000. Zeke Capital Advisors LLC raised its position in UroGen Pharma by 39.8% in the 2nd quarter. Zeke Capital Advisors LLC now owns 722,875 shares of the company’s stock worth $11,038,000 after buying an additional 205,769 shares during the last quarter. Finally, Horton Capital Management LLC raised its position in UroGen Pharma by 9.0% in the 3rd quarter. Horton Capital Management LLC now owns 684,749 shares of the company’s stock worth $11,517,000 after buying an additional 56,674 shares during the last quarter.
Shares of URGN traded up $0.72 during trading hours on Thursday, hitting $12.76. The company had a trading volume of 95,608 shares, compared to its average volume of 146,389. The firm has a fifty day moving average price of $16.48 and a 200-day moving average price of $16.39. The stock has a market capitalization of $266.68 million, a price-to-earnings ratio of -2.54 and a beta of 1.18. UroGen Pharma has a 52-week low of $11.67 and a 52-week high of $28.20.
UroGen Pharma Company Profile
UroGen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases. It has developed RTGel reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs.
Recommended Story: Portfolio Manager
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for UroGen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UroGen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.